Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Importance of genetic screens in precision oncology.
Mulero-Sánchez A, Pogacar Z, Vecchione L. Mulero-Sánchez A, et al. ESMO Open. 2019 May 24;4(3):e000505. doi: 10.1136/esmoopen-2019-000505. eCollection 2019. ESMO Open. 2019. PMID: 31231569 Free PMC article. Review.
Paradoxical activation of oncogenic signaling as a cancer treatment strategy.
Dias MH, Friskes A, Wang S, Fernandes Neto JM, van Gemert F, Mourragui S, Papagianni C, Kuiken HJ, Mainardi S, Alvarez-Villanueva D, Lieftink C, Morris B, Dekker A, van Dijk E, Wilms LHS, da Silva MS, Jansen RA, Mulero-Sanchez A, Malzer E, Vidal A, Santos C, Salazar R, Wailemann RAM, Torres TEP, De Conti G, Raaijmakers JA, Snaebjornsson P, Yuan S, Qin W, Kovach JS, Armelin HA, Te Riele H, van Oudernaarden A, Jin H, Beijersbergen RL, Villanueva A, Medema RH, Bernards R. Dias MH, et al. Among authors: mulero sanchez a. Cancer Discov. 2024 Mar 27. doi: 10.1158/2159-8290.CD-23-0216. Online ahead of print. Cancer Discov. 2024. PMID: 38533987
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Frank KJ, Mulero-Sánchez A, Berninger A, Ruiz-Cañas L, Bosma A, Görgülü K, Wu N, Diakopoulos KN, Kaya-Aksoy E, Ruess DA, Kabacaoğlu D, Schmidt F, Kohlmann L, van Tellingen O, Thijssen B, van de Ven M, Proost N, Kossatz S, Weber WA, Sainz B Jr, Bernards R, Algül H, Lesina M, Mainardi S. Frank KJ, et al. Among authors: mulero sanchez a. Cell Rep Med. 2022 Nov 15;3(11):100815. doi: 10.1016/j.xcrm.2022.100815. Cell Rep Med. 2022. PMID: 36384095 Free PMC article.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mulero-Sánchez A, et al. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. Mol Oncol. 2023. PMID: 36650715 Free PMC article.
Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero-Sánchez A, Morris B, Roosen M, Wardak L, De Conti G, Velds A, Lieftink C, Thijssen B, Beijersbergen RL, Bernards R, Leite de Oliveira R. Pogacar Z, et al. Among authors: mulero sanchez a. Life Sci Alliance. 2022 May 9;5(9):e202101348. doi: 10.26508/lsa.202101348. Print 2022 Sep. Life Sci Alliance. 2022. PMID: 35534224 Free PMC article.
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R. Mainardi S, et al. Among authors: mulero sanchez a. Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28. Nat Med. 2018. PMID: 29808006 Free article.